Drug survival of the first and second course of antitumour necrosis factor agents in juvenile idiopathic arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 4, 2009, Pages 552-557

  Tynjala P ^a,b,d   Vahasalo P ^c   Honkanen, V ^a   Lahdenne, P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Lohja Hospital   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SURVIVAL; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; KAPLAN MEIER METHOD; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIERS ESTIMATE; MALE; METHOTREXATE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 65249121332     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.087130     Document Type: Article

References (26)

1. Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:271-5.
2. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201.
3. Ruperto N, Ravelli A, Castell E, Gerloni V, Haefner R, Malattia C, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006;24:599-605.
4. Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional antiinflammatory medication. Eur J Ophthalmol 2007;17:743-8.
5. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
6. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.
7. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7.
8. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106.
9. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006;65:753-9.
10. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007;66:548-50.
11. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5.
12. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Opthalmol 2007;91:319-24.
13. Foeldvari I, Nielsen S, Kummerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritisassociated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007;34:1146-50.
14. Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47:339-44.
15. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94.
16. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
17. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
18. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
19. Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research Alliance, PRINTO, Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
20. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
21. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-42.
22. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitisrelated arthritis. J Rheumatol 2004;31:2055-61.
23. Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005;52:2103-8.
24. Flato B, Lien G, Smerdel A, Vinje O, Dale K, Johnston V, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol 2003;30:386-93.
25. Gare BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process. J Rheumatol 1995;22:295-307.
26. Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt Study. J Rheumatol Suppl 2007;80:25-33.